Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.58 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | CCR5 | P51681 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6261222 | 0.87 | HTT (0.68) | SMN1; SMN2HTTALDH1A1USP28USP25 | |
| SCHEMBL6259187 | 0.84 | PPIA (0.55) | SMN1; SMN2ALDH1A1USP28USP25LMNA | |
| SCHEMBL6258926 | 0.83 | CCR5 (0.55) | SMN1; SMN2ALDH1A1USP28USP25LMNA | |
| SCHEMBL8155926 | 0.82 | CCR5 (0.50) | SMN1; SMN2HTTALDH1A1USP28USP25 | |
| SCHEMBL8162193 | 0.82 | CCR5 (0.50) | SMN1; SMN2HTTALDH1A1USP28USP25 | |
| SCHEMBL8703991 | 0.82 | CCR5 (0.50) | SMN1; SMN2HTTALDH1A1USP28USP25 | |
| SCHEMBL6257530 | 0.82 | PPIA (0.50) | HTTALDH1A1USP28USP25LMNA | |
| SCHEMBL8162946 | 0.82 | CCR5 (0.49) | SMN1; SMN2HTTALDH1A1USP28USP25 | |
| SCHEMBL8161862 | 0.82 | GAA (0.49) | SMN1; SMN2HTTALDH1A1USP28USP25 | |
| SCHEMBL6260658 | 0.79 | PTGER1 (0.46) | ALDH1A1USP28USP25LMNACCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0752421-B1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ASTRAZENECA AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| US-6787562-B2 | ANALGESICS; OSTEOPOROSIS | ZENECA LTD. (GB) | 2004-09-07 | — | — | US | disclosed |
| US-20030139418-A1 | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists | SYNGENTA LIMITED (GB) | 2003-07-24 | — | — | US | disclosed |
| US-6057345-A | ANTAGONISTS OF THE PAIN ENHANCING EFFECTS OF E-TYPE PROSTAGLANDINS; USED IN PAIN RELIEF | ZENECA LIMITED (GB) | 2000-05-02 | — | — | US | disclosed |
| US-5834468-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANALGESICS TREATING RHEUMATIC DISEASE, BONE DISORDER, INJURIES | ZENECA LIMITED (GB) | 1998-11-10 | — | — | US | disclosed |
| EP-0752421-A1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ZENECA LIMITED (GB) | 1997-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139418-A1 | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists | PTGER1, PTGDR, PTGER2 | SMN1; SMN2 2519/4885HTT 4559/4885ALDH1A1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.